Financial Express — January 20, 2022. Routine prescription of azithromycin to COVID-19 patients with no evidence of its efficacy against COVID-19 will have a devastating impact on AMR in coming years, according to Ramanan Laxminarayan of the Center for Disease Dynamics, Economics and Policy.